Latcha Sheron
Renal Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Semin Dial. 2019 May;32(3):215-218. doi: 10.1111/sdi.12780. Epub 2019 Mar 20.
Age is a risk factor for both cancer and end-stage renal disease (ESRD). Newer cancer treatments are allowing patients to live longer with their cancer, the renal toxicity from the cancer itself or from the therapies that was used to treat the malignancy. Consequently, nephrologists will increasingly be asked to evaluate and counsel patients with ESRD and advanced cancer regarding the initiation of dialysis. Data on morbidity, mortality, and quality of life (QOL) outcomes in this population are sparse. Expectations regarding what dialysis can reasonably accomplish in this cohort can be unrealistically high among patients, their family members and the rest of the health care team. This article will discuss some results from the available studies on mortality and QOL outcomes in this cohort and advise the nephrologist about how to approach these challenging discussions.
年龄是癌症和终末期肾病(ESRD)的一个风险因素。新型癌症治疗方法使癌症患者能够存活更长时间,这是由于癌症本身或用于治疗恶性肿瘤的疗法具有肾毒性。因此,肾病学家将越来越多地被要求就透析的启动对患有ESRD和晚期癌症的患者进行评估和咨询。关于这一人群的发病率、死亡率和生活质量(QOL)结果的数据很少。患者、其家庭成员和其他医疗团队成员对透析在这一队列中能够合理实现的目标的期望可能过高。本文将讨论该队列中现有关于死亡率和QOL结果的研究的一些结果,并就肾病学家如何进行这些具有挑战性的讨论提供建议。